Table 3.
Demographics: pwMS and pwNIc who tested positive to COVID-19 post tixagevimab/cilgavimab administration
| pwMS and pwNIc who received tixagevimab/cilgavimab who tested positive to COVID-19 during observation follow-up | Total n=32 |
| Age (years) | |
| Min | 33 |
| Max | 67 |
| Mean | 49.47 |
| SD | 10.75 |
| Sex, n (%) | |
| Female | 25 (78.1%) |
| EDSS | |
| Min | 0 |
| Max | 6.5 |
| Mean | 2.45 |
| SD | 1.86 |
| DMT n (%) | |
| Ocrelizumab | 22 (68.75%) |
| Rituximab | 3 (9.38%) |
| Fingolimod | 5 (15.63%) |
| Siponimod | 1 (3.12%) |
| Other | 1 (3.12%) |
| COVID-19 n (%) vaccine dose no | |
| 2 | 2 (6.25%) |
| 3 | 9 (28.13%) |
| 4 | 17 (53.13%) |
| 5 | 4 (12.5%) |
| COVID-19 positive n (%) | |
| Tixagevimab/cilgavimab during observation window | 32/167 (19.16%) |
| Prior to tixagevimab/cilgavimab availability | 15/32 (46.88%) |
| Days from administration to COVID-19 positive n (days) | |
| Min | 3 |
| Max | 178 |
| Mean | 99 |
| SD | 52.34 |
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale Score; pwMS, people with multiple sclerosis; pwNIc, people with neuroimmunological conditions.